Viewing Study NCT00916656


Ignite Creation Date: 2025-12-24 @ 11:19 PM
Ignite Modification Date: 2026-01-01 @ 5:16 PM
Study NCT ID: NCT00916656
Status: WITHDRAWN
Last Update Posted: 2023-02-06
First Post: 2009-06-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Fibrinogen Concentrate (Human) - Efficacy and Safety Study
Sponsor: CSL Behring
Organization:

Study Overview

Official Title: Efficacy and Safety of Fibrinogen Concentrate (Human) (FCH) for On-demand Treatment of Acute Bleeding in Subjects With Congenital Fibrinogen Deficiency
Status: WITHDRAWN
Status Verified Date: 2023-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human).

It is estimated that 150-300 patients in the U.S. suffer from afibrinogenemia. Substitution with cryoprecipitate or alternative treatments have limited safety and efficacy.

The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma) in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia). Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used as a historical control.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
1475 OTHER CSL Behring View
2007-004088-22 EUDRACT_NUMBER None View